National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
    Cancer Studies Highlighted in the NCI Cancer Bulletin  
 
Page Options
Print This Page
E-Mail This Document
Search by Cancer Type
Breast Cancer

Colon and Rectal Cancer

Lung Cancer

Prostate Cancer

More Featured Trials
Search Featured Trials

      
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
You Can Quit Smoking Now!
Related Pages
Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.

Thyroid Cancer Home Page
NCI's gateway for information about thyroid cancer.
Thyroid Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

1.  New Drug for Patients with Advanced Thyroid Cancer
(Posted: 11/18/2008) - In this phase II trial, researchers are studying the effects of treatment with 17-AAG, an antitumor antibiotic drug that targets a protein called HSP90, in patients with advanced medullary or differentiated thyroid cancer.

2.  Treating Hereditary Thyroid Cancer in Children
(Posted: 12/18/2007) - In this clinical trial, doctors are testing a new drug called vandetanib (Zactima) in young patients with advanced hereditary medullary thyroid cancer. Vandetanib targets the specific genetic defect responsible for these tumors.

3.  Targeted Combination Therapy for Advanced Solid Tumors
(Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov